This Article Full Text Full Text (PDF) All Versions of this Article: 90/2/805    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Saravanan, P. Articles by Dayan, C. M. Search for Related Content PubMed PubMed Citation Articles by Saravanan, P. Articles by Dayan, C. M. Related Collections Thyroid

Partial Substitution of Thyroxine (T₄) with Tri-Iodothyronine in Patients on T₄ Replacement Therapy: Results of a Large Community-Based Randomized Controlled Trial

Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology (P.S., D.J.S., C.M.D.) and Academic Unit of Primary Health Care, Department of Community-Based Medicine (T.J.P.), University of Bristol, Bristol BS1 3NY, United Kingdom; and Research and Development Support Unit (R.G.), Bristol Royal Infirmary, Bristol BS2 8HW, United Kingdom

Address all correspondence and requests for reprints to: Dr. Colin M. Dayan, Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology, Dorothy Hodgkin Building, University of Bristol, Whitson Street, Bristol BS1 3NY, United Kingdom. E-mail: colin.dayan{at}bris.ac.uk.

Conflicting results have recently been published about the benefits of combined T₄ and T₃ in treating hypothyroid patients. However, these studies may have been underpowered to detect differences in psychological well-being specifically related to T₄ replacement. We conducted a large, double-blind, randomized controlled trial of partial substitution of 50 µg T₄ by 10 µg T₃ vs. the original dose of T₄ in 697 hypothyroid patients. Thyroid function showed a rise in TSH (132%), a fall in free T₄ (35%, P < 0.001), and unchanged basal free T₃ levels (P = 0.92). At 3 months, there was a large (39%) placebo effect improvement in psychiatric caseness defined by the General Health Questionnaire (GHQ) 12 score in the control group compared with baseline, and this was sustained at 12 months. Differences vs. the intervention (T₃) group were more modest with improvements in GHQ caseness (odds ratio, 0.61; 95% confidence interval, 0.42, 0.90; P = 0.01) and Hospital Anxiety and Depression questionnaire-anxiety scores at 3 months (P < 0.03) but not GHQ Likert scores, Hospital Anxiety and Depression questionnaire-depression, thyroid symptoms, or visual analog scales of mood and the initial differences were lost at 12 months. These results may be consistent with a subgroup of patients showing transient improvement after partial substitution with T₃ but do not provide conclusive evidence of specific benefit from partial substitution of T₄ by T₃ in patients on T₄ replacement. They also emphasize the large and sustained placebo effect that can follow changes in thyroid hormone administration.

This article has been cited by other articles:

				J. Jonklaas, B. Davidson, S. Bhagat, and S. J. Soldin Triiodothyronine Levels in Athyreotic Individuals During Levothyroxine Therapy JAMA, February 20, 2008; 299(7): 769 - 777. [Abstract] [Full Text] [PDF]

				R. T. Joffe, M. Brimacombe, A. J. Levitt, and A. Stagnaro-Green Treatment of Clinical Hypothyroidism With Thyroxine and Triiodothyronine: A Literature Review and Metaanalysis Psychosomatics, October 1, 2007; 48(5): 379 - 384. [Abstract] [Full Text] [PDF]

				P. Saravanan, T. J. Visser, and C. M. Dayan Psychological Well-Being Correlates with Free Thyroxine But Not Free 3,5,3'-Triiodothyronine Levels in Patients on Thyroid Hormone Replacement J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3389 - 3393. [Abstract] [Full Text] [PDF]

				J. P. Walsh, L. C. Ward, V. Burke, C. I. Bhagat, L. Shiels, D. Henley, M. J. Gillett, R. Gilbert, M. Tanner, and B. G. A. Stuckey Small Changes in Thyroxine Dosage Do Not Produce Measurable Changes in Hypothyroid Symptoms, Well-Being, or Quality of Life: Results of a Double-Blind, Randomized Clinical Trial J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2624 - 2630. [Abstract] [Full Text] [PDF]

				S. Grozinsky-Glasberg, A. Fraser, E. Nahshoni, A. Weizman, and L. Leibovici Thyroxine-Triiodothyronine Combination Therapy Versus Thyroxine Monotherapy for Clinical Hypothyroidism: Meta-Analysis of Randomized Controlled Trials J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2592 - 2599. [Abstract] [Full Text] [PDF]

				H. F. Escobar-Morreale, J. I. Botella-Carretero, F. E. del Rey, and G. M. de Escobar Treatment of Hypothyroidism with Combinations of Levothyroxine plus Liothyronine J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4946 - 4954. [Abstract] [Full Text] [PDF]